For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody ...

B7-H3 targeted therapies present promising market opportunities due to the protein's significant presence in various cancers and low expression in normal tissues. With over 15 candidates in clinical ...

DelveInsight’s B7-H3 Inhibitor Market Insights report includes a comprehensive understanding of current treatment practices, emerging B7-H3 inhibitors, market share of individual therapies, and ...

GT Biopharma Inc. GTBP on Thursday dosed the first patient on a Phase 1 dose-escalation basket trial evaluating GTB-5550, its ...

GTB-5550 is now the 3rd TriKE® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to ...

Issued on behalf of GT Biopharma, Inc. Key Takeaways - First patient dosed in Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager — the third TriKE® program to enter clinical ...

B7-H3–directed CAR T-cell therapy showed safety and tolerability in recurrent glioblastoma patients, with no dose-limiting toxicities or severe adverse effects observed. The study achieved a 44% ...

Targeting CHK1 pathway to induce cytotoxic response to histone deactylase inhibitors and evaluating the synergistic effects of CHK1 and HDAC inhibitors in human soft tissue sarcoma cell lines and ...

Artios Pharma Limited (“Artios”), a clinical-stage biopharmaceutical company pioneering the development of new classes of DNA Damage Response (DDR) medicines to deliver meaningful survival benefits ...